Live Breaking News & Updates on Markus Muttenthaler|Page 2

Stay updated with breaking news from Markus muttenthaler. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Using Nature's strategies in the development of new drugs


 E-Mail
Dimerization (Note: combination of two identical or different molecules) of the human neuropeptides oxytocin and vasopressin can produce new types of bioactive molecules. In a recent study, an international research team led by MedUni Vienna and the University of Vienna demonstrated that dimerized and therefore significantly larger versions of oxytocin and vasopressin are still able to activate their receptors. Such new constructs provide several opportunities to optimize the efficacy of these neuropeptides for therapeutic application. The researchers were inspired for this approach from naturally occurring dimers. The results have been published in the journal
Chemical Science .
Oxytocin/vasopressin receptors are typical examples of so-called G protein-coupled receptors - the most successful drug target class. The oxytocin and vasopressin receptors are targeted, for example, during childbirth to encourage contractions but are also being investigated for the ....

Christian Gruber , Markus Muttenthaler , Institute Of Pharmacology , University Of Vienna , Meduni Vienna , Uni Vienna , Biological Chemistry , Medicine Health , Pharmaceutical Science , Pharmaceutical Chemistry , கிறிஸ்துவர் க்ரூபர் , நிறுவனம் ஆஃப் மருந்தியல் , பல்கலைக்கழகம் ஆஃப் வியன்னா , யூனி வியன்னா , உயிரியல் வேதியியல் , மருந்து ஆரோக்கியம் , மருந்து அறிவியல் , மருந்து வேதியியல் ,

Therapeutic potential of peptides


Date Time
Therapeutic potential of peptides
Currently there are more than 80 peptide drugs on the global market and about twice as many in clinical development. Due to their beneficial properties, these biomolecules play already an important role in the treatment of diseases such as diabetes, cancer, hormone disorders, HIV infection, and multiple sclerosis. In the recent issue of “Nature Reviews Drug Discovery”, a team of Austrian and Australian scientists led by medicinal chemist Markus Muttenthaler of the University of Vienna present an outlook on the latest trends in peptide drug discovery and development.
“Insulin is a prime example for a successful peptide drug that has been essential for the health of millions of diabetic patients in the past 100 years,” says Markus Muttenthaler, who leads research groups at the Institute of Biological Chemistry of the Faculty of Chemistry at University in Vienna as well as at the Institute for Molecular Bioscience, at th ....

Christophe Duplais , Thomas Durek , Lucie Jaquillard , Nayara Braga Emidio , Philipe Dawson , Davidj Adams , Fernandac Cardoso , Christophe Duplai , Axel Touchard , Mathilde Triquigneaux , Isabelle Boulogne , Helenc Mendel , Andrewa Walker , Alicia Peschel , Markus Muttenthaler , Volker Herzig , Alain Dejean , Paulf Alewood , Olivier Delalande , Glennf King , Institute For Molecular Bioscience , University Of Queensland , University Of Vienna , Reviews Drug , Biological Chemistry , Molecular Bioscience ,